Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
AIMOVIG™
(erenumab-aooe) injection, for subcutaneous use
Erenumab-aooe is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to the calcitonin gene-related peptide receptor. Erenumab-aooe is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa.
AIMOVIG (erenumab-aooe) injection is supplied as a sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous administration. Each 1 mL single-dose prefilled autoinjector and single-dose prefilled glass syringe contains 70 mg erenumab-aooe, acetate (1.5 mg), polysorbate 80 (0.10 mg), and sucrose (73 mg). Enclosed within the autoinjector is a single-dose, prefilled glass syringe. The solution of AIMOVIG has a pH of 5.2.
AIMOVIG is indicated for the preventive treatment of migraine in adults.
The recommended dosage of AIMOVIG is 70 mg injected subcutaneously once monthly. Some patients may benefit from a dosage of 140 mg injected subcutaneously once monthly, which is administered as two consecutive subcutaneous injections of 70 mg each.
If a dose of AIMOVIG is missed, administer as soon as possible. Thereafter, AIMOVIG can be scheduled monthly from the date of the last dose.
AIMOVIG is for subcutaneous use only.
The needle shield within the white cap of the AIMOVIG prefilled autoinjector and gray needle cap of the AIMOVIG prefilled syringe contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex.
AIMOVIG is intended for patient self-administration. Prior to use, provide proper training to patients and/or caregivers on how to prepare and administer AIMOVIG using the single-dose prefilled autoinjector or single-dose prefilled syringe, including aseptic technique [see Instructions For Use]:
AIMOVIG is a sterile, clear to opalescent, colorless to light yellow solution available as follows:
AIMOVIG (erenumab-aooe) injection is a sterile, clear to opalescent, colorless to light yellow solution for subcutaneous administration.
The needle shield within the white cap of the AIMOVIG prefilled autoinjector and gray needle cap of the AIMOVIG prefilled syringe contain dry natural rubber (a derivative of latex). Each single-dose prefilled SureClick® autoinjector or single-dose prefilled syringe of AIMOVIG contains a Type 1 glass syringe andstainless steel needle and delivers 1 mL of 70 mg/mL solution.
AIMOVIG is supplied as follows:
Pack of 1 autoinjector: 70 mg/mL single-dose prefilled autoinjector NDC 55513-841-01
Pack of 2 autoinjectors: 140 mg/2 mL (2 x 70 mg/mL single-dose prefilled autoinjectors) NDC 55513-841-02
Pack of 1 syringe: 70 mg/mL single-dose prefilled syringe NDC 55513-840-01
Pack of 2 syringes: 140 mg/2 mL (2 x 70 mg/mL single-dose prefilled syringes) NDC 55513-840-02
AIMOVIG™ (erenumab-aooe), Manufactured by: Amgen Inc. One Amgen Center Drive, Thousand Oaks, CA 91320-1799 USA, U.S. License No. 1080. Marketed by: Amgen Inc. (Thousand Oaks, CA 91320), and Novartis Pharmaceuticals Corporation (East Hanover, NJ 07936). Revised: May 2018
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of AIMOVIG has been evaluated in 2,537 patients with migraine who received at least one dose of AIMOVIG, representing 2,310 patient-years of exposure. Of these, 2,057 patients were exposed to 70 mg or 140 mg once monthly for at least 6 months, 1,198 patients were exposed for at least 12 months, and 287 patients were exposed for at least 18 months.
In placebo-controlled clinical studies (Studies 1, 2, and 3) of 2,184 patients, 787 patients received at least one dose of AIMOVIG 70 mg once monthly, 507 patients received at least one dose of AIMOVIG 140 mg once monthly, and 890 patients received placebo during 3 months or 6 months of double-blind treatment [see Clinical Studies]. Approximately 84% were female, 91% were white, and the mean age was 42 years at study entry.
The most common adverse reactions (incidence ≥ 3% and more often than placebo) in the migraine studies were injection site reactions and constipation. Table 1 summarizes the adverse reactions that occurred during the first 3 months in the migraine studies (Studies 1, 2, and 3).
Table 1: Adverse Reactions Occurring with an Incidence
of at Least 2% for Either Dose of AIMOVIG and at Least 2% Greater than Placebo
During the First 3 Months in Studies 1, 2, and 3
| Adverse Reaction | AIMOVIG 70 mg Once Monthly N = 787 % |
AIMOVIG 140 mg Once Monthly N = 507 % |
Placebo N = 890 % |
| Injection site reactionsa | 6 | 5 | 3 |
| Constipation | 1 | 3 | 1 |
| Cramps, muscle spasms | < 1 | 2 | < 1 |
| aInjection site reactions include multiple adverse reactions related terms, such as injection site pain and injection site erythema. | |||
In Studies 1, 2, and 3, 1.3% of patients treated with AIMOVIG discontinued double-blind treatment because of adverse events. The most frequent injection site reactions were injection site pain, injection site erythema, and injection site pruritus.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation, including neutralizing antibodies, is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to erenumab-aooe in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.
The immunogenicity of AIMOVIG has been evaluated using an immunoassay for the detection of binding anti-erenumab-aooe antibodies. For patients whose sera tested positive in the screening immunoassay, an in vitro biological assay was performed to detect neutralizing antibodies.
In controlled studies with AIMOVIG, the incidence of anti-erenumab-aooe antibody development was 6.2% (48/778) in patients receiving AIMOVIG 70 mg once monthly (2 of whom had in vitro neutralizing activity) and 2.6% (13/504) in patients receiving AIMOVIG 140 mg once monthly (none of whom had in vitro neutralizing activity). The neutralizing anti-erenumab-aooe antibody positive rate may be underestimated because of limitations of the assay. Although these data do not demonstrate an impact of anti-erenumab-aooe antibody development on the efficacy or safety of AIMOVIG in these patients, the available data are too limited to make definitive conclusions.
No Information provided
No Information provided
No Information provided
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).
Provide guidance to patients and caregivers on proper subcutaneous administration technique, including aseptic technique, and how to use the single-dose prefilled autoinjector or single-dose prefilled syringe [see DOSAGE AND ADMINISTRATION]. Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use AIMOVIG.
Instruct patients prescribed 140 mg to administer the once monthly dosage as two separate subcutaneous injections of 70 mg each.
Advise latex-sensitive patients that the needle shield within the white cap of the AIMOVIG prefilled autoinjector and gray needle cap of the AIMOVIG prefilled syringe contain dry natural rubber (a derivative of latex) that may cause allergic reactions in individuals sensitive to latex [see DOSAGE AND ADMINISTRATION].
For more information, go to www.aimovig.com or call 1-800-77-AMGEN (1-800-772-6436).
The carcinogenic potential of erenumab-aooe has not been assessed.
Genetic toxicology studies of erenumab-aooe have not been conducted.
Mating studies have not been conducted on erenumab-aooe. No histopathological changes in male or female reproductive organs were observed in monkeys administered erenumab-aooe (0, 25, or 150 mg/kg) by subcutaneous injection twice weekly for up to 6 months. Serum erenumab-aooe exposures (AUC) at the higher dose tested were more than 100 times that in humans at a dose of 140 mg once monthly.
There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women. No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation (see Data). Serum erenumab-aooe exposures in pregnant monkeys were greater than those in humans at clinical doses.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.
Disease-Associated Maternal And/Or Embryo/Fetal Risk
Published data have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy.
Animal Data
In a study in which female monkeys were administered erenumab-aooe (0 or 50 mg/kg) twice weekly by subcutaneous injection throughout pregnancy (gestation day 20-22 to parturition), no adverse effects on offspring were observed. Serum erenumab-aooe exposures (AUC) in pregnant monkeys were approximately 20 times that in humans at a dose of 140 mg once monthly.
There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AIMOVIG and any potential adverse effects on the breastfed infant from AIMOVIG or from the underlying maternal condition.
Safety and effectiveness in pediatric patients have not been established.
Clinical studies of AIMOVIG did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
No Information provided
None.
Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
In a randomized, double-blind, placebo-controlled study in healthy volunteers, concomitant administration of erenumab-aooe (140 mg intravenous, single-dose) with sumatriptan (12 mg subcutaneous, given as two 6 mg doses separated by one hour) had no effect on resting blood pressure compared with sumatriptan alone. AIMOVIG is for subcutaneous use only.
Erenumab-aooe exhibits non-linear kinetics as a result of binding to the CGRP receptor. The Cmax mean and AUClast mean following subcutaneous administration of a 70 mg once monthly and a 140 mg once monthly dose in healthy volunteers or migraine patients are included in Table 2.
Less than 2-fold accumulation was observed in trough serum concentrations (Cmin) for episodic and chronic migraine patients following subcutaneous administration of 70 mg once monthly and 140 mg once monthly doses (see Table 2). Serum trough concentrations approached steady state by 3 months of dosing. The effective half-life of erenumab-aooe is 28 days.
Table 2: Pharmacokinetic Parameters of AIMOVIG
| AIMOVIG 70 mg Subcutaneously Once Monthly | AIMOVIG 140 mg Subcutaneously Once Monthly | |
| Cmax mean (SD)a,b | 6.1 (2.1) mcg/mL | 15.8 (4.8) mcg/mL |
| AUClast mean (SD)a,b | 159 (58) day*mcg/mL | 505 (139) day*mcg/mL |
| Cmin (SD) | ||
| Episodic migraine | 5.7 (3.1) mcg/mL | 12.8 (6.5) mcg/mL |
| Chronic migraine | 6.2 (2.9) mcg/mL | 14.9 (6.5) mcg/mL |
| a SD = standard deviation b from a single-dose study |
||
Following a single subcutaneous dose of 70 mg or 140 mg erenumab-aooe administered to healthy adults, median peak serum concentrations were attained in approximately 6 days, and estimated absolute bioavailability was 82%.
Following a single 140 mg intravenous dose, the mean (SD) volume of distribution during the terminal phase (Vz) was estimated to be 3.86 (0.77) L.
Two elimination phases were observed for erenumab-aooe. At low concentrations, the elimination is predominantly through saturable binding to target (CGRP receptor), while at higher concentrations the elimination of erenumab-aooe is largely through a non-specific, non-saturable proteolytic pathway.
The pharmacokinetics of erenumab-aooe were not affected by age, gender, race, or subtypes of migraine spectrum (episodic or chronic migraine) based on population pharmacokinetics analysis.
Population pharmacokinetic analysis of integrated data from the AIMOVIG clinical studies did not reveal a difference in the pharmacokinetics of erenumab-aooe in patients with mild or moderate renal impairment relative to those with normal renal function. Patients with severe renal impairment (Egfr < 30 mL/min/1.73 m²) have not been studied. No dedicated clinical studies were conducted to evaluate the effect of hepatic impairment or renal impairment on the pharmacokinetics of erenumab-aooe. Renal or hepatic impairment is not expected to affect pharmacokinetics of erenumab-aooe.
Erenumab-aooe is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.
In an open-label drug interaction study in healthy female volunteers, erenumab-aooe (140 mg subcutaneous, single-dose) did not affect the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
In a study in healthy volunteers, concomitant administration of erenumab-aooe with sumatriptan had no effect on the pharmacokinetics of sumatriptan [see CLINICAL PHARMACOLOGY].
The efficacy of AIMOVIG was evaluated as a preventive treatment of episodic or chronic migraine in three randomized, double-blind, placebo-controlled studies: two studies in patients with episodic migraine (4 to 14 migraine days per month) (Study 1 and Study 2) and one study in patients with chronic migraine (≥ 15 headache days per month with ≥ 8 migraine days per month) (Study 3). The studies enrolled patients with a history of migraine, with or without aura, according to the International Classification of Headache Disorders (ICHD-III) diagnostic criteria.
Study 1 (NCT 02456740) was a randomized, multi-center, 6-month, placebo-controlled, double-blind study evaluating AIMOVIG for the preventive treatment of episodic migraine. A total of 955 patients with a history of episodic migraine were randomized to receive either AIMOVIG 70 mg (N = 317), AIMOVIG 140 mg (N = 319), or placebo (N = 319) by subcutaneous injection once monthly (QM) for 6 months. Patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives) and NSAIDs during the study.
The study excluded patients with medication overuse headache as well as patients with myocardial infarction, stroke, transient ischemic attacks, unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months prior to screening.
The primary efficacy endpoint was the change from baseline in mean monthly migraine days over months 4 to 6. Secondary endpoints included the achievement of a ≥ 50% reduction from baseline in mean monthly migraine days over months 4 to 6 (“≥ 50% MMD responders”), the change from baseline in mean monthly acute migraine-specific medication days over months 4 to 6, and the change from baseline in mean Migraine Physical Function Impact Diary (MPFID) over months 4 to 6. The MPFID measures the impact of migraine on everyday activities (EA) and physical impairment (PI) using an electronic diary administered daily. Monthly MPFID scores are averaged over 28 days, including days with and without migraine; scores are scaled from 0 to 100. Higher scores indicate worse impact on EA and PI. Reductions from baseline in MPFID scores indicate improvement.
A total of 858 (90%) patients completed the 6-month double-blind study. Patients had a median age of 42 years (range: 18 to 65 years), 85% were female, and 89% were white. Three percent of patients were taking concomitant preventive treatments for migraine. The mean migraine frequency at baseline was approximately 8 migraine days per month and was similar across treatment groups.
AIMOVIG treatment demonstrated statistically significant improvements for key efficacy endpoints compared to placebo, as summarized in Table 3.
Table 3: Efficacy Endpoints Over Months 4 to 6 in Study 1
| AIMOVIG 70 mg Once Monthly N = 312 |
AIMOVIG 140 mg Once Monthly N = 318 |
Placebo N = 316 |
|
| Monthly Migraine Days (MMD) | |||
| Change from baseline | -3.2 | -3.7 | -1.8 |
| Difference from placebo | -1.4 | -1.9 | |
| p-value | <0.001 | <0.001 | |
| ≥ 50% MMD responders | |||
| % Responders | 43.3% | 50.0% | 26.6% |
| Difference from placebo | 16.7% | 23.4% | |
| Odds ratio relative to placebo | 2.1 | 2.8 | |
| p-value | <0.001 | <0.001 | |
| Monthly acute migraine-specific medication days | |||
| Change from baseline | -1.1 | -1.6 | -0.2 |
| Difference from placebo | -0.9 | -1.4 | |
| p-value | <0.001 | <0.001 | |
Figure 1: Change from Baseline in Monthly Migraine Days in Study 1a
 |
Figure 2 shows the distribution of change from baseline in mean monthly migraine days over months 4 to 6 in bins of 2 days by treatment group. A treatment benefit over placebo for both doses of AIMOVIG is seen across a range of changes from baseline in monthly migraine days.
Figure 2: Distribution of Change from Baseline in Mean
Monthly Migraine Days over Months 4 to 6 by Treatment Group in Study 1
 |
Compared to placebo, patients treated with AIMOVIG 70 mg once monthly and 140 mg once monthly showed greater reductions from baseline in mean monthly MPFID everyday activity scores averaged over months 4 to 6 [difference from placebo: -2.2 for AIMOVIG 70 mg and -2.6 for AIMOVIG 140 mg; p-value < 0.001 for both], and in mean monthly MPFID physical impairment scores averaged over months 4 to 6 [difference from placebo: -1.9 for AIMOVIG 70 mg and -2.4 for AIMOVIG 140 mg; p-value < 0.001 for both].
Study 2 (NCT 02483585) was a randomized, multi-center, 3-month, placebo-controlled, double-blind study evaluating AIMOVIG for the preventive treatment of episodic migraine. A total of 577 patients with a history of episodic migraine were randomized to receive either AIMOVIG 70 mg (N = 286) or placebo (N = 291) by subcutaneous injection once monthly for 3 months. Patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives) and NSAIDs during the study.
The study excluded patients with medication overuse headache as well as patients with myocardial infarction, stroke, transient ischemic attacks, unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months prior to screening.
The primary efficacy endpoint was the change from baseline in monthly migraine days at month 3. Secondary endpoints included the achievement of a ≥ 50% reduction from baseline in monthly migraine days (“≥ 50% MMD responders”), the change from baseline in monthly acute migraine-specific medication days at month 3, and the proportion of patients with at least a 5-point score reduction from baseline in MPFID at month 3.
A total of 546 (95%) patients completed the 3-month double-blind study. Patients had a median age of 43 years (range: 18 to 65 years), 85% were female, and 90% were white. Six to seven percent of patients were taking concomitant preventive migraine treatment. The mean migraine frequency at baseline was approximately 8 migraine days per month and was similar between treatment groups.
AIMOVIG treatment demonstrated statistically significant improvements for key efficacy endpoints compared to placebo, as summarized in Table 4.
Table 4: Efficacy Endpoints at Month 3 for Study 2
| AIMOVIG 70 mg Once Monthly N = 282 |
Placebo N = 288 |
|
| Monthly Migraine Days (MMD) | ||
| Change from baseline | -2.9 | -1.8 |
| Difference from placebo | -1.0 | |
| p-value | <0.001 | |
| ≥ 50% MMD responders | ||
| % Responders | 39.7% | 29.5% |
| Difference from placebo | 10.2% | |
| Odds ratio relative to placebo | 1.6 | |
| p-value | 0.010 | |
| Monthly acute migraine-specific medication days | ||
| Change from baseline | -1.2 | -0.6 |
| Difference from placebo | -0.6 | |
| p-value | 0.002 | |
Figure 3: Change from Baseline in Monthly Migraine
Days in Study 2a
 |
Figure 4 shows the distribution of change from baseline in monthly migraine days at month 3 in bins of 2 days by treatment group. A treatment benefit over placebo for AIMOVIG is seen across a range of changes from baseline in monthly migraine days.
Figure 4: Distribution of Change from Baseline in
Monthly Migraine Days at Month 3 by Treatment Group in Study 2
 |
The pre-specified analysis for the MPFID was based on at least a 5-point reduction within-patient responder definition. AIMOVIG 70 mg once monthly was not significantly better than placebo for the proportion of responders for everyday activity [difference from placebo: 4.7%; odds ratio = 1.2; p-value = 0.26] and physical impairment [difference from placebo: 5.9%; odds ratio = 1.3; p-value = 0.13]. In an exploratory analysis of the change from baseline in the mean MPFID scores at month 3, patients treated with AIMOVIG 70 mg, as compared to placebo, showed nominally greater reductions of physical impairment scores [difference from placebo: -1.3; p-value = 0.021], but not of everyday activities scores [difference from placebo: -1.1; p-value = 0.061].
Study 3 (NCT 02066415) was a randomized, multi-center, 3-month, placebo-controlled, double-blind study evaluating AIMOVIG as a preventive treatment of chronic migraine. A total of 667 patients with a history of chronic migraine with or without aura were randomized to receive AIMOVIG 70 mg (N = 191), AIMOVIG 140 mg (N = 190), or placebo (N = 286) by subcutaneous injections once monthly for 3 months. Patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives) and NSAIDs during the study.
The study excluded patients with medication overuse headache caused by opiate overuse and patients with concurrent use of migraine preventive treatments. Patients with myocardial infarction, stroke, transient ischemic attacks, unstable angina, coronary artery bypass surgery, or other revascularization procedures within 12 months prior to screening were also excluded.
The primary efficacy endpoint was the change from baseline in monthly migraine days at month 3. Secondary endpoints included the achievement of a ≥ 50% reduction from baseline in monthly migraine days (“≥ 50% MMD responders”) and change from baseline in monthly acute migraine-specific medication days at month 3.
 A total of 631 (95%) patients completed the 3-month double-blind study. Patients had a median age of 43 years (range: 18 to 66 years), 83% were female, and 94% were white. The mean migraine frequency at baseline was approximately 18 migraine days per month and was similar across treatment groups.
AIMOVIG treatment demonstrated statistically significant improvements for key efficacy outcomes compared to placebo, as summarized in Table 5.
Table 5: Efficacy Endpoints at Month 3 in Study 3
| AIMOVIG 70 mg Once Monthly N = 188 |
AIMOVIG 140 mg Once Monthly N = 187 |
Placebo N = 281 |
|
| Monthly Migraine Days (MMD) | |||
| Change from baseline | -6.6 | -6.6 | -4.2 |
| Difference from placebo | -2.5 | -2.5 | |
| p-value | <0.001 | <0.001 | |
| ≥ 50% MMD responders | |||
| % Responders | 39.9% | 41.2% | 23.5% |
| Difference from placebo | 16.4% | 17.7% | |
| Odds ratio relative to placebo | 2.2 | 2.3 | |
| p-value | <0.001 | <0.001 | |
| Monthly acute migraine-specific medication days | |||
| Change from baseline | -3.5 | -4.1 | -1.6 |
| Difference from placebo | -1.9 | -2.6 | |
| p-value | <0.001 | <0.001 | |
Figure 5: Change from Baseline in Monthly Migraine
Days in Study 3a
 |
Figure 6 shows the distribution of change from baseline in monthly migraine days at month 3 in bins of 3 days by treatment group. A treatment benefit over placebo for both doses of AIMOVIG is seen across a range of changes from baseline in migraine days.
Figure 6: Distribution of Change from Baseline in
Monthly Migraine Days at Month 3 by Treatment Group in Study 3
 |
AIMOVIG™
(AIM-oh-vig)
(erenumab-aooe) injection, for subcutaneous use
What is AIMOVIG?
AIMOVIG is a prescription medicine used for the preventive treatment of migraine in adults.
It is not known if AIMOVIG is safe and effective in children under 18 years of age.
Before you start using AIMOVIG, tell your healthcare provider about all your medical conditions, including if you are:
Tell your pharmacist or healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.
How should I take AIMOVIG?
What are possible side effects of AIMOVIG?
The most common side effects of AIMOVIG include: pain, redness, or swelling at the injection site and constipation.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of AIMOVIG. Ask your pharmacist or healthcare provider for more information.
Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800- FDA-1088. You may also report side effects to Amgen at 1-800-77-AMGEN (1-800-772-6436).
How should I store AIMOVIG?
Keep AIMOVIG and all medicines out of the reach of children.
General information about the safe and effective use of AIMOVIG.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use AIMOVIG for a condition for which it is not prescribed. Do not give AIMOVIG to other people, even if they have the same symptoms that you have. It can harm them. You can ask your pharmacist or healthcare provider for information about AIMOVIG that is written for healthcare professionals.
What are the ingredients in AIMOVIG?
Instructions for Use
AIMOVIG™
(AIM-oh-vig)
(erenumab-aooe) Injection, For Subcutaneous Use
Single-Dose Prefilled SureClick® Autoinjector
Guide to parts
 |
Important: Needle is inside
Important
Before you use AIMOVIG SureClick autoinjector, read this important information:
Storing your AIMOVIG SureClick autoinjector
Using your AIMOVIG SureClick autoinjector
Step 1: Prepare
STOP Read this before you inject.
Check your prescription.
AIMOVIG comes as a single-dose (1 time) prefilled autoinjector. Your healthcare provider will prescribe the dose that is best for you.
Before you inject, always check the label of your single-dose prefilled autoinjector to make sure you have the correct medicine and the correct dose of AIMOVIG.
A Remove autoinjector from the carton. You may need to use more than 1 autoinjector based on your prescribed dose.
Carefully lift the autoinjector straight up out of the carton.
Leave the autoinjector at room temperature for at least 30 minutes before injecting.
B. Inspect the autoinjector.
 |
Make sure the medicine in the window is clear and colorless to slightly yellow.
In all cases, use a new autoinjector, and call 1-800-77-AMGEN (1-800-772-6436).
C. Gather all materials needed for your injection.
Wash your hands thoroughly with soap and water.
On a clean, well-lit work surface, place the:
 |
D. Prepare and clean your injection site.
 |
You can use:
Clean your injection site with an alcohol wipe. Let your skin dry.
Step 2: Get ready
E. Pull the white cap straight off, only when you are ready to inject. Do not leave the white cap off for more than 5 minutes. This can dry out the medicine.
 |
It is normal to see a drop of liquid at the end of the needle or green safety guard.
F. Stretch or pinch your injection site to create a firm surface.
Stretch method
 |
Stretch skin firmly by moving your thumb and fingers in opposite directions, creating an area about 2 inches wide.
OR
Pinch method
 |
Pinch skin firmly between your thumb and fingers, creating an area about 2 inches wide.
Important: Keep skin stretched or pinched while injecting.
Step 3: Inject
G. Hold the stretch or pinch. With the white cap off, place the autoinjector on your skin at 90 degrees.
 |
Important: Do not touch the purple start button yet.
H. Firmly push the autoinjector down onto skin until the autoinjector stops moving.
 |
Important: You must push all the way down but do not touch the purple start button until you are ready to inject.
I. When you are ready to inject, press the purple start button. You will hear a click.
 |
J. Keep pushing down on your skin. Your injection could take about 15 seconds. When the injection is complete, you may hear or feel a click and the window will turn yellow.
 |
Note: After you remove the autoinjector from your skin, the needle will be automatically covered.
 |
Important: When you remove the autoinjector, if the window has not turned yellow, or if it looks like the medicine is still injecting, this means you have not received a full dose. Call your healthcare provider immediately.
Step 4: Finish
K. Discard the used autoinjector and the white cap.
 |
Put the used AIMOVIG autoinjector and white cap in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) the SureClick autoinjector in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal
Important: Always keep the sharps disposal container out of the reach of children.
L. Examine the injection site.
If there is blood, press a cotton ball or gauze pad on your injection site. Do not rub the injection site. Apply an adhesive bandage if needed.
M. Check your prescription. If your dose is 140 mg, repeat Steps 1 through 4.
The second injection will complete your dose.
Commonly asked questions
What will happen if I press the purple start button before I am ready to do the injection on my skin?
Even when you press the purple start button, the injection will only happen when the green safety guard is also pushed into the autoinjector.
Can I move the autoinjector around on my skin while I am choosing an injection site?
It is okay to move the autoinjector around on the injection site as long as you do not press the purple start button. However, if you press the purple start button and the green safety guard is pushed into the autoinjector, the injection will begin.
Can I release the purple start button after I start my injection?
You can release the purple start button, but continue to hold the autoinjector firmly against your skin during the injection.
Will the purple start button pop up after I release my thumb?
The purple start button may not pop up after you release your thumb if you held your thumb down during the injection. This is okay.
What do I do if I did not hear a click after pushing the device down on my skin for 15 seconds?
If you did not hear a click, you can confirm a complete injection by checking that the window has turned yellow.
Whom do I contact if I need help with the autoinjector or my injection?
If you need more information or help, visit www.aimovig.com or call 1-800-77- AMGEN (1-800-772-6436).
For more information, go to www.aimovig.com or call 1-800-77-AMGEN (1-800-772- 6436).
 |
Instructions for Use
AIMOVIG™
(AIM-oh-vig)
(erenumab-aooe) Injection, For Subcutaneous Use
Single-Dose Prefilled Syringe
Guide to parts
 |
Important: Needle is inside
Important
Before you use AIMOVIG prefilled syringe, read this important information:
Storing your AIMOVIG prefilled syringe
Using your AIMOVIG prefilled syringe
Step 1: Prepare
STOP Read this before you inject.
Check your prescription.
AIMOVIG comes as a single-dose (1 time) prefilled syringe. Your healthcare provider will prescribe the dose that is best for you.
Before you inject, always check the label of your single-dose prefilled syringe to make sure you have the correct medicine and the correct dose of AIMOVIG.
A. Remove AIMOVIG prefilled syringe from the carton. You may need to use more than 1 prefilled syringe based on your prescribed dose.
Grab the syringe barrel to remove the syringe from the tray.
Place finger or thumb on edge of tray to secure it while you remove the syringe.
 |
Grab Here
 |
For safety reasons:
Leave the syringe at room temperature for at least 30 minutes before injecting.
Important: Always hold the prefilled syringe by the syringe barrel.
B. Inspect the AIMOVIG prefilled syringe.
 |
Always hold the syringe by the syringe barrel.
Make sure the medicine in the syringe is clear and colorless to slightly yellow.
In all cases, use a new syringe, and call 1-800-77-AMGEN (1-800-772-6436).
C. Gather all materials needed for your injection. Wash your hands thoroughly with soap and water. On a clean, well-lit work surface, place the:
 |
D. Prepare and clean your injection site.
 |
You can use:
Clean your injection site with an alcohol wipe. Let your skin dry.
Step 2: Get ready
E. Pull gray needle cap straight out and away from your body, only when you are ready to inject. Do not leave the gray needle cap off for more than 5 minutes. This can dry out the medicine.
 |
It is normal to see a drop of liquid at the end of the needle.
Important: Throw the gray needle cap into the sharps disposal container.
F. Pinch your injection site to create a firm surface.
 |
Pinch skin firmly between your thumb and fingers, creating an area about 2 inches wide.
Important: Keep skin pinched while injecting.
Step 3: Inject
G. Hold the pinch. With the gray needle cap off, insert the syringe into your skin at 45 to 90 degrees.
 |
Do not place your finger on the plunger rod while inserting the needle.
H. Place your finger on the plunger rod. Using slow and constant pressure, push the plunger rod all the way down until the prefilled syringe stops moving.
 |
I. When done, release your thumb, and gently lift the syringe off of your skin.
 |
Important: When you remove the syringe, if it looks like the medicine is still in the syringe barrel, this means you have not received a full dose. Call your healthcare provider immediately.
Step 4: Finish
J. Discard the used syringe and the gray needle cap.
 |
Put the used AIMOVIG syringe and gray needle cap in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) the syringe in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
Important: Always keep the sharps disposal container out of the reach of children.
K Examine the injection site.
If there is blood, press a cotton ball or gauze pad on your injection site. Do not rub the injection site. Apply an adhesive bandage if needed.
L Check your prescription. If your dose is 140 mg, repeat Steps 1 through 4. The second injection will complete your dose.
For more information, go to www.aimovig.com or call 1-800-77-AMGEN (1-800-772-6436).
 |
This Instructions for Use has been approved by the U.S. Food and Drug Association.
